Trevi Therapeutics, Inc. (TRVI) stock
TRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.29−0.36 (-2.64%)
Close on Nov 16, 2026Market cap $1.89BP/E –Yield –
Trevi Therapeutics cash
Cash and short-term investments held at the end of each period.
Trevi Therapeutics's cash was $318.87M at Jun 30, 2026. For fiscal 2025 it was $188.26M, up 74.9% from the year before. The highest annual figure on record is $188.26M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $188.26M | +74.9% |
| FY2024 | Dec 31, 2024 | $107.62M | +29.7% |
| FY2023 | Dec 31, 2023 | $82.97M | -31.2% |
| FY2022 | Dec 31, 2022 | $120.51M | +227.2% |
| FY2021 | Dec 31, 2021 | $36.83M | -18.2% |
| FY2020 | Dec 31, 2020 | $45.00M | -21.5% |
| FY2019 | Dec 31, 2019 | $57.31M | +695.8% |
| FY2018 | Dec 31, 2018 | $7.20M | -67.3% |
| FY2017 | Dec 31, 2017 | $22.02M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $318.87M | +56.4% |
| Q1 FY2026 | Mar 31, 2026 | $171.78M | +66.4% |
| Q4 FY2025 | Dec 31, 2025 | $188.26M | +74.9% |
| Q3 FY2025 | Sep 30, 2025 | $194.93M | +197.6% |
| Q2 FY2025 | Jun 30, 2025 | $203.89M | +193.4% |
| Q1 FY2025 | Mar 31, 2025 | $103.26M | +41.8% |
| Q4 FY2024 | Dec 31, 2024 | $107.62M | +29.7% |
| Q3 FY2024 | Sep 30, 2024 | $65.49M | -26.3% |
| Q2 FY2024 | Jun 30, 2024 | $69.50M | -26.2% |
| Q1 FY2024 | Mar 31, 2024 | $72.82M | -34.5% |
| Q4 FY2023 | Dec 31, 2023 | $82.97M | -31.2% |
| Q3 FY2023 | Sep 30, 2023 | $88.87M | -29.2% |
| Q2 FY2023 | Jun 30, 2023 | $94.15M | +20.9% |
| Q1 FY2023 | Mar 31, 2023 | $111.26M | +282.2% |
| Q4 FY2022 | Dec 31, 2022 | $120.51M | +227.2% |
| Q3 FY2022 | Sep 30, 2022 | $125.60M | +328.4% |
| Q2 FY2022 | Jun 30, 2022 | $77.86M | +113.7% |
| Q1 FY2022 | Mar 31, 2022 | $29.11M | -30.0% |
| Q4 FY2021 | Dec 31, 2021 | $36.83M | -18.2% |
| Q3 FY2021 | Sep 30, 2021 | $29.32M | -45.0% |
| Q2 FY2021 | Jun 30, 2021 | $36.43M | -17.6% |
| Q1 FY2021 | Mar 31, 2021 | $41.57M | -21.0% |
| Q4 FY2020 | Dec 31, 2020 | $45.00M | -21.5% |
| Q3 FY2020 | Sep 30, 2020 | $53.29M | -16.1% |
| Q2 FY2020 | Jun 30, 2020 | $44.18M | -38.1% |
| Q1 FY2020 | Mar 31, 2020 | $52.64M | +306.6% |
| Q4 FY2019 | Dec 31, 2019 | $57.31M | +695.8% |
| Q3 FY2019 | Sep 30, 2019 | $63.52M | +369.3% |
| Q2 FY2019 | Jun 30, 2019 | $71.39M | +911.4% |
| Q1 FY2019 | Mar 31, 2019 | $12.95M | -18.9% |
| Q4 FY2018 | Dec 31, 2018 | $7.20M | -67.3% |
| Q3 FY2018 | Sep 30, 2018 | $13.53M | – |
| Q2 FY2018 | Jun 30, 2018 | $7.06M | – |
| Q1 FY2018 | Mar 31, 2018 | $15.96M | – |
| Q4 FY2017 | Dec 31, 2017 | $22.02M | – |
See a number that looks wrong?